Search Result
Results for "
Benzamide
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-Z0283
-
Benzenecarboxamide; Phenylamide
|
Endogenous Metabolite
PARP
|
Others
|
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
|
-
-
- HY-Z0283S
-
Benzenecarboxamide-15N; Phenylamide-15N
|
Endogenous Metabolite
PARP
|
Others
|
Benzamide- 15N is a 15N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].
|
-
-
- HY-B1224
-
2-(Hexyloxy)Benzamide
|
Fungal
|
Infection
|
Exalamide (2-(Hexyloxy)benzamide), an arenecarboxamide, is a potent antifungal agent .
|
-
-
- HY-145488
-
|
ADC Linker
|
Cancer
|
MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-Z0283R
-
|
Endogenous Metabolite
PARP
|
Others
|
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
|
-
-
- HY-U00415
-
|
Dopamine Receptor
mAChR
|
Neurological Disease
|
Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.
|
-
-
- HY-147342
-
|
Others
|
Others
|
β-Benzamide adenine dinucleotide is a bioactive metabolite of benzamide nucleoside and a potent inhibitor of inosine 5 '-monophosphate dehydrogenase (IMPDH). β-Benzamide adenine dinucleotide is a potent, competitive inhibitor of human NAD kinase (Ki = 90 µM) .
|
-
-
- HY-W714833
-
-
-
- HY-147256
-
-
-
- HY-N13189
-
|
Others
|
Cardiovascular Disease
|
cis-N-(4-Hydroxystyryl)benzamide is a platelet aggregation inhibitor that can be isolated from the chloroform extract of Houttuynia cordata, a traditional Chinese medicine .
|
-
-
- HY-W698474
-
-
-
- HY-W128037
-
-
-
- HY-B1883S
-
|
Isotope-Labeled Compounds
|
Others
|
3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is the deuterium labeled 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide[1]. 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-134753
-
4-Amino-N-(4-trifluoromethylphenyl)Benzamide
|
COX
|
Inflammation/Immunology
|
Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective COX-1 inhibitor with an IC50 of 30 µM. Teriflunomide impurity 3 is less active against COX-2 (IC50>100 µM) .
|
-
-
- HY-Q49697
-
-
-
- HY-149800
-
|
PARP
Apoptosis
Caspase
|
Cancer
|
PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC50 values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .
|
-
-
- HY-U00020
-
|
Others
|
Metabolic Disease
|
AU-224 is a benzamide derivative used as a promising gastrointestinal prokinetic agent without significant side effects.
|
-
-
- HY-B1059
-
RV-12309; S-(-)-Sulpiride
|
Dopamine Receptor
|
Neurological Disease
|
Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class.
|
-
-
- HY-12505
-
CX546
3 Publications Verification
|
iGluR
Autophagy
|
Neurological Disease
|
CX546 is a first-generation and selective benzamide-type positive AMPAR modulator. CX546 is a prototypical ampakine agent and has antipsychotic effects .
|
-
-
- HY-100963
-
-
-
- HY-112731
-
-
-
- HY-B0068
-
Y-25130 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
Azasetron (Y-25130) hydrochloride, a benzamide derivative, is a potent and selective 5-HT3 receptor antagonist. Azasetron is used in the study for Chemotherapy-induced nausea and vomiting (CINV) .
|
-
-
- HY-120469
-
|
JAK
|
Inflammation/Immunology
|
GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with Kis of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .
|
-
-
- HY-B1059S
-
RV-12309-d3; S-(-)-Sulpiride-d3
|
Isotope-Labeled Compounds
Dopamine Receptor
|
Neurological Disease
|
Levosulpiride-d3 is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class[1][2].
|
-
-
- HY-B1059R
-
|
Dopamine Receptor
|
Neurological Disease
|
Levosulpiride (Standard) is the analytical standard of Levosulpiride. This product is intended for research and analytical applications. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class.
|
-
-
- HY-B0732S
-
-
-
- HY-B1019
-
Sulpiride
Maximum Cited Publications
7 Publications Verification
|
Dopamine Receptor
|
Neurological Disease
|
Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer .
|
-
-
- HY-103414
-
|
Dopamine Receptor
|
Neurological Disease
|
Raclopride is a dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively .
|
-
-
- HY-108976
-
|
Dopamine Receptor
|
Neurological Disease
|
Raclopride tartrate is a selective dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively .
|
-
-
- HY-151370
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
AChE-IN-26 (compound 4a) is an AChE (acetylcholinesterase) inhibitor with an IC50 value of 0.42 μM. AChE-IN-26 can be used for the research of Alzheimer’s disease .
|
-
-
- HY-155597
-
|
NTPDase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
h-NTPDase8-IN-1 (compound 2d) is a sulfamoyl-benzamides based and selective inhibitor for h-NTPDases8 (IC50=0.28 μM). h-NTPDases8 is involved in a variety of physiological and pathological functions,such as thrombosis,diabetes,inflammation,and cancer .
|
-
-
- HY-U00121
-
|
5-HT Receptor
|
Metabolic Disease
|
Lintopride, a benzamide, is a potent 5HT-4 antagonist with moderate 5HT-3 antagonist properties. Lintopride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animal. Lintopride significantly increases the lower oesophageal sphincter (LOS) basal tone .
|
-
-
- HY-112547
-
CRT0066051
|
PKD
|
Others
|
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .
|
-
-
- HY-163502
-
|
PROTACs
STAT
|
Cancer
|
PROTAC STAT3 degrader-3 (S3D1) is a STAT3 PROTAC degrader with anticancer activity (Structural notes: (Blue: Cereblon ligand (HY-10984), Black: linker; Pink: Pentafluorobenzenesulfonamide(Me)-CH2-CONH-benzamide (HY-163526)) .
|
-
-
- HY-U00121A
-
|
5-HT Receptor
|
Metabolic Disease
|
Lintopride hydrochloride, a benzamide, is a potent 5HT-4 antagonist with moderate 5HT-3 antagonist properties. Lintopride hydrochloride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animal. Lintopride hydrochloride significantly increases the lower oesophageal sphincter (LOS) basal tone .
|
-
-
- HY-P4154
-
ALM-488
|
Fluorescent Dye
|
Neurological Disease
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
-
- HY-101313
-
(-)-Remoxipride
|
Dopamine Receptor
|
Neurological Disease
|
(S)-Remoxipride ((-)-Remoxipride) is a selective dopamine D2-receptor antagonist with an IC50 value of 1.57 μM. (S)-Remoxipride can be used for the research of psychotic disorder .
|
-
-
- HY-101313A
-
(-)-Remoxipride hydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
(S)-Remoxipride ((-)-Remoxipride) hydrochloride is a selective dopamine D2-receptor antagonist with an IC50 value of 1.57 μM. (S)-Remoxipride hydrochloride can be used for the research of psychotic disorder .
|
-
-
- HY-14147
-
BRL 24924
|
5-HT Receptor
|
Metabolic Disease
|
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .
|
-
-
- HY-B1019R
-
|
Dopamine Receptor
|
Neurological Disease
|
Sulpiride (Standard) is the analytical standard of Sulpiride. This product is intended for research and analytical applications. Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer .
|
-
-
- HY-P1103A
-
|
CXCR
|
Cancer
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
-
- HY-P1103
-
|
CXCR
|
Cancer
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
-
- HY-145815
-
|
HDAC
PROTACs
|
Cancer
|
JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC). JPS014 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .
|
-
-
- HY-145816
-
|
HDAC
PROTACs
|
Cancer
|
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .
|
-
-
- HY-145818
-
|
HDAC
PROTACs
|
Cancer
|
JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .
|
-
-
- HY-145819
-
|
HDAC
PROTACs
|
Cancer
|
JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .
|
-
-
- HY-145816A
-
|
HDAC
PROTACs
|
Cancer
|
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .
|
-
-
- HY-124894
-
|
Fungal
|
Infection
|
(+)-Benalaxyl is a broad-spectrum benzamide fungicide. (+)-Benalaxyl inhibits the growth of the freshwater algae S. obliquus, with an EC50 value of 8.441 mg/L. (+)-Benalaxyl can induce the production of chlorophyll a and b, as well as increase the activity of superoxide dismutase (SOD) and the generation of malondialdehyde (MDA). (+)-Benalaxyl has inhibitory effects on catalase (CAT). (+)-Benalaxyl is effective against diseases caused by oomycetes .
|
-
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-145815A
-
|
PROTACs
HDAC
Apoptosis
|
Cancer
|
JPS014 TFA is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 TFA degrades class I histone deacetylase (HDAC). JPS014 TFA is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells .
|
-
- HY-155355
-
|
iGluR
|
Neurological Disease
|
LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke .
|
-
- HY-14148
-
|
Others
|
Neurological Disease
|
Renzapride hydrochloride is a benzamide that inhibits irritable bowel syndrome and has antagonistic activity at 5-HT(3) receptors and agonistic activity at 5-HT(4) receptors. Renzapride hydrochloride also exhibits antagonistic activity at 5-HT(2B) receptors and has a certain affinity for 5-HT(2A) and 5-HT(2C) receptors .
|
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P1321
-
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
- HY-W357200
-
N-[9-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-9H-purin-6-yl]-Benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
N6-Benzoyl-7’-OH-N-trityl morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357201
-
N-[1-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-Benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
N4-Benzoyl-7’-OH-N-trityl morpholino cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-15056
-
|
TRP Channel
|
Inflammation/Immunology
|
AMG 9090 is characterized as a compound that acts as a partial agonist of rat TRPA1 channels, demonstrating pharmacological activity in pain and inflammation models. TRPA1 is pivotal in sensing reactive compounds, triggering pain responses in humans and rodents. AMG 9090, along with other trichloro(sulfanyl)ethyl benzamides (TCEB compounds), shows differential effects on human and rat TRPA1 channels: it acts as a potent antagonist of human TRPA1 activated by AITC and noxious cold, whereas it behaves as a partial agonist at rat TRPA1. This suggests AMG 9090's potential as a therapeutic agent targeting TRPA1-mediated pain and inflammation, with additional inhibitory activity against TRPM8 noted .
|
-
- HY-146123
-
-
Cat. No. |
Product Name |
Type |
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4154
-
ALM-488
|
Fluorescent Dye
|
Neurological Disease
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-P1103
-
|
CXCR
|
Cancer
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P10026
-
LY-3457263
|
Peptides
|
Metabolic Disease
|
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .
|
-
- HY-W128037
-
-
- HY-P1103A
-
|
CXCR
|
Cancer
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P4757
-
|
Peptides
|
Others
|
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
|
-
- HY-P1321
-
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-Z0283S
-
|
Benzamide- 15N is a 15N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].
|
-
-
- HY-B1059S
-
|
Levosulpiride-d3 is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class[1][2].
|
-
-
- HY-B1883S
-
|
3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is the deuterium labeled 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide[1]. 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-B0732S
-
|
Itopride-d6 (hydrochloride) is deuterium labeled Itopride (hydrochloride). Itopride hydrochloride (HSR803), a gastroprokinetic Benzamide (HY-Z0283) derivative, is an inhibitor of acetylcholinesterase (AChE) and dopamine D2 receptor[1][2].
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-B1883S
-
|
|
Alkynes
|
3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is the deuterium labeled 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide[1]. 3,5-Dichloro-N-(2-methylbut-3-yn-2-yl)benzamide-d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: